facebook linkedin twitter

FDA Changes Prescribing Instructions for Controversial Alzheimer’s Drug

July 8, 2021 by Dan McCue

U.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug.

The announcement came through Biogen Inc., the maker of Aduhelm, which stated the update is intended to “clarify” the patients studied in the company trials that led to approval.

The new labeling approved by the FDA state’s the drug is appropriate for patients exhibiting signs of mild cognitive impairment or mild dementia.

When the drug was first approved a top FDA official told reporters the drug was “relevant to all stages of Alzheimer’s disease.”

But that led to weeks of blowback and consternation. The FDA then approached the company about narrowing the label and approved the language to address confusion among physicians and patients.

The FDA now warns that there is “no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.” 

Biogen’s head of research and development, Dr. Alfred Sandrock, Jr. said the new labeling is based “on our ongoing conversations with prescribing physicians, FDA and patient advocates. 

“We submitted this label update with the goal to further clarify the patient population that was studied across the three Aduhelm clinical trials that supported approval,” he added.

Despite the update, the FDA added that “some patients may benefit from ongoing treatment” if they develop more advanced Alzheimer’s.

The label change comes one month after FDA’s approval of the drug, which quickly sparked controversy over its $56,000-a-year price-tag and questionable benefits. 

Three of FDA’s outside advisers resigned over the decision with one prominent Harvard expert calling it the “worst drug approval decision in recent U.S. history.”

Prescription Drugs

November 24, 2021
by Tom Ramstack
Ohio Jury Faults Pharmacies for Spurring Opioid Epidemic

CLEVELAND, Ohio — A landmark jury verdict Tuesday could make major pharmacy chains like CVS, Walgreens and Walmart liable for... Read More

CLEVELAND, Ohio — A landmark jury verdict Tuesday could make major pharmacy chains like CVS, Walgreens and Walmart liable for encouraging the opioid epidemic that kills thousands of Americans each year.  The verdict in federal court in Ohio is the first to uphold a legal theory... Read More

November 19, 2021
by Tom Ramstack
Lawsuit Against Opioid Companies Blames COVID-19 for Aggravating Crisis

SEATTLE — Testimony this week during a civil trial in Seattle could explain why opioid deaths set a record of... Read More

SEATTLE — Testimony this week during a civil trial in Seattle could explain why opioid deaths set a record of more than 100,000 in a year by last April. The class action lawsuit seeks $95 billion in damages against pharmaceutical companies that distribute the powerful painkillers.... Read More

November 2, 2021
by Dan McCue
Schumer, Pelosi, Moderates Strike Deal to Lower Prescription Drug Prices

WASHINGTON — Senate Majority Leader Chuck Schumer, D-N.Y., announced Tuesday that Democrats have reached a deal on legislation to lower... Read More

WASHINGTON — Senate Majority Leader Chuck Schumer, D-N.Y., announced Tuesday that Democrats have reached a deal on legislation to lower prescription drug prices. "It's not everything we all wanted. Many of us would have wanted to go much further, but it's a big step in helping... Read More

Merck Says Experimental Pill Cuts Worst Effects of COVID-19

WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people... Read More

WASHINGTON (AP) — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. If cleared,... Read More

September 14, 2021
by Dan McCue
Moderates Seek Changes to Drug Pricing Proposal

A group of moderate Democrats led by Rep. Scott Peters sought on Tuesday to change the House debate on how... Read More

A group of moderate Democrats led by Rep. Scott Peters sought on Tuesday to change the House debate on how prescription drug prices are set in the U.S., arguing sweeping proposals put forward by progressives could threaten passage of the $3.5 trillion budget bill. The push... Read More

September 9, 2021
by Dan McCue
White House Unveils Plan to Cut Prescription-Drug Prices

WASHINGTON -- The Biden administration on Thursday offered the first detailed look at actions the White House may take in... Read More

WASHINGTON -- The Biden administration on Thursday offered the first detailed look at actions the White House may take in conjunction with congressional action to lower prescription drug prices. The 29-page plan, released through the Department of Health and Human Services, backs the intention of many... Read More

News From The Well
scroll top